BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15297772)

  • 1. Safety of infliximab in patients suffering from inflammatory bowel disease.
    Felley C; Michetti P
    Digestion; 2004; 70(1):1-2. PubMed ID: 15297772
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital.
    Seiderer J; Göke B; Ochsenkühn T
    Digestion; 2004; 70(1):3-9. PubMed ID: 15297773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is keeping the colon the ultimate marker of success in ulcerative colitis?
    Nguyen GC; Prather CM
    Gastroenterology; 2009 Oct; 137(4):1204-6. PubMed ID: 19717125
    [No Abstract]   [Full Text] [Related]  

  • 4. Infliximab in ulcerative colitis.
    Aberra FN; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Dec; 35(4):821-36. PubMed ID: 17129815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of manic switch by the tumour necrosis factor-alpha antagonist infliximab.
    Elisa B; Beny L
    Psychiatry Clin Neurosci; 2010 Aug; 64(4):442-3. PubMed ID: 20653912
    [No Abstract]   [Full Text] [Related]  

  • 6. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis.
    Fratila OC; Craciun C
    J Gastrointestin Liver Dis; 2010 Jun; 19(2):147-53. PubMed ID: 20593047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
    Sandborn WJ; Rutgeerts P; Feagan BG; Reinisch W; Olson A; Johanns J; Lu J; Horgan K; Rachmilewitz D; Hanauer SB; Lichtenstein GR; de Villiers WJ; Present D; Sands BE; Colombel JF
    Gastroenterology; 2009 Oct; 137(4):1250-60; quiz 1520. PubMed ID: 19596014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study.
    Gustavsson A; Järnerot G; Hertervig E; Friis-Liby I; Blomquist L; Karlén P; Grännö C; Vilien M; Ström M; Verbaan H; Hellström PM; Magnuson A; Halfvarson J; Tysk C
    Aliment Pharmacol Ther; 2010 Oct; 32(8):984-9. PubMed ID: 20937043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
    Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
    J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab for ulcerative colitis following liver transplantation.
    Lal S; Steinhart AH
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):277-80. PubMed ID: 17301656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Retrobulbar optic neuritis during infliximab treatment for ulcerative colitis].
    Hejazi R; Colombel JF; Peyrin-Biroulet L
    Gastroenterol Clin Biol; 2008 Feb; 32(2):162-3. PubMed ID: 18387427
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of the anti-tumour necrosis factor monoclonal antibody--infliximab--to treat ulcerative colitis: implications and trends beyond the available data.
    Rossetti S; Actis GC; Fadda M; Rizzetto M; Palmo A
    Dig Liver Dis; 2004 Jun; 36(6):426-31. PubMed ID: 15248385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Disseminated salmonella infection with aortic mycotic aneurysm in a ulcerative colitis patient treated with infliximab].
    Corberand D; Bredin C; Gizard E; Sava C; Rey P
    Presse Med; 2013 Dec; 42(12):1658-60. PubMed ID: 23688701
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
    Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab: new indication. Ulcerative colitis: caution is needed due to long-term risks.
    Prescrire Int; 2007 Oct; 16(91):194. PubMed ID: 17926832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe rosacea in a patient on infliximab for ulcerative colitis: pathophysiological considerations.
    Kosmidou M; Gaitanis G; Nomikos K; Zioga A; Katsanos K; Bassukas ID; Tsianos E
    Acta Derm Venereol; 2009; 89(5):522-3. PubMed ID: 19734983
    [No Abstract]   [Full Text] [Related]  

  • 19. Is infliximab effective for induction of remission in patients with ulcerative colitis?
    Lichtenstein GR
    Inflamm Bowel Dis; 2001 May; 7(2):89-93. PubMed ID: 11383596
    [No Abstract]   [Full Text] [Related]  

  • 20. Infliximab in refractory severe ulcerative colitis: a case report.
    Bossa F; Caserta L; Selvaggi F; Riegler G
    Minerva Gastroenterol Dietol; 2005 Sep; 51(3):261-2. PubMed ID: 16280968
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.